Role of PTEN in modulation of ADP-dependent signaling pathways in vascular endothelial cells

Biochimica et Biophysica Acta - Molecular Cell Research

Volumn 1833, Issue 12, 2013, Pages 2586-2595

  Bretón Romero, Rosa ^a,b   Kalwa, Hermann ^a   Lamas, Santiago ^b   Michel, Thomas ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

Author keywords

ADP; Endothelium; Nitric oxide; Phosphoinositides

Indexed keywords

ADENOSINE DIPHOSPHATE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GLYCEROPHOSPHORYLINOSITOL 4,5 BISPHOSPHATE; INOSITOL PHOSPHATE; MITOGEN ACTIVATED PROTEIN KINASE P38; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; RAC1 PROTEIN; SMALL INTERFERING RNA;

ANIMAL CELL; ARTICLE; BIOSENSOR; CELL MIGRATION; CONTROLLED STUDY; DEPHOSPHORYLATION; ENDOTHELIUM CELL; ENZYME ACTIVITY; FLUORESCENCE RESONANCE ENERGY TRANSFER; NONHUMAN; PRIORITY JOURNAL; PROTEIN INTERACTION; PROTEIN PHOSPHORYLATION; RNA INTERFERENCE; SECOND MESSENGER; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIUM;

EID: 84881104386     PISSN: 01674889     EISSN: 18792596     Source Type: Journal    
DOI: 10.1016/j.bbamcr.2013.06.009     Document Type: Article

References (55)

1. Erlinge D., Burnstock G. P2 receptors in cardiovascular regulation and disease. Purinergic Signal 2008, 4:1-20.
2. Ralevic V., Burnstock G. Involvement of purinergic signaling in cardiovascular diseases. Drug News Perspect. 2003, 16:133-140.
3. Hess C.N., Kou R., Johnson R.P., Li G.K., Michel T. ADP signaling in vascular endothelial cells: ADP-dependent activation of the endothelial isoform of nitric-oxide synthase requires the expression but not the kinase activity of AMP-activated protein kinase. J. Biol. Chem. 2009, 284:32209-32224.
4. Michel T., Vanhoutte P.M. Cellular signaling and NO production. Pflugers Arch. 2010, 459:807-816.
5. Kolluru G.K., Siamwala J.H., Chatterjee S. eNOS phosphorylation in health and disease. Biochimie 2010, 92:1186-1198.
6. Mount P.F., Kemp B.E., Power D.A. Regulation of endothelial and myocardial NO synthesis by multi-site eNOS phosphorylation. J. Mol. Cell. Cardiol. 2007, 42:271-279.
7. Li J., Yen C., Liaw D., Podsypanina K., Bose S., Wang S.I., Puc J., Miliaresis C., Rodgers L., McCombie R., Bigner S.H., Giovanella B.C., Ittmann M., Tycko B., Hibshoosh H., Wigler M.H., Parsons R. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997, 275:1943-1947.
8. Steck P.A., Pershouse M.A., Jasser S.A., Yung W.K., Lin H., Ligon A.H., Langford L.A., Baumgard M.L., Hattier T., Davis T., Frye C., Hu R., Swedlund B., Teng D.H., Tavtigian S.V. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat. Genet. 1997, 15:356-362.
9. Downes C.P., Walker S., McConnachie G., Lindsay Y., Batty I.H., Leslie N.R. Acute regulation of the tumour suppressor phosphatase, PTEN, by anionic lipids and reactive oxygen species. Biochem. Soc. Trans. 2004, 32:338-342.
10. Waite K.A., Eng C. Protean PTEN: form and function. Am. J. Hum. Genet. 2002, 70:829-844.
11. Ferguson K.M., Kavran J.M., Sankaran V.G., Fournier E., Isakoff S.J., Skolnik E.Y., Lemmon M.A. Structural basis for discrimination of 3-phosphoinositides by pleckstrin homology domains. Mol. Cell 2000, 6:373-384.
12. Church J.E., Qian J., Kumar S., Black S.M., Venema R.C., Papapetropoulos A., Fulton D.J. Inhibition of endothelial nitric oxide synthase by the lipid phosphatase PTEN. Vasc. Pharmacol. 2010, 52:191-198.
13. Leslie N.R., Batty I.H., Maccario H., Davidson L., Downes C.P. Understanding PTEN regulation: PIP2, polarity and protein stability. Oncogene 2008, 27:5464-5476.
14. Lee S.R., Yang K.S., Kwon J., Lee C., Jeong W., Rhee S.G. Reversible inactivation of the tumor suppressor PTEN by H2O2. J. Biol. Chem. 2002, 277:20336-20342.
15. Vazquez F., Ramaswamy S., Nakamura N., Sellers W.R. Phosphorylation of the PTEN tail regulates protein stability and function. Mol. Cell. Biol. 2000, 20:5010-5018.
16. Tamura M., Gu J., Matsumoto K., Aota S., Parsons R., Yamada K.M. Inhibition of cell migration, spreading, and focal adhesions by tumor suppressor PTEN. Science 1998, 280:1614-1617.
17. Tamura M., Gu J., Takino T., Yamada K.M. Tumor suppressor PTEN inhibition of cell invasion, migration, and growth: differential involvement of focal adhesion kinase and p130Cas. Cancer Res. 1999, 59:442-449.
18. Dey N., Crosswell H.E., De P., Parsons R., Peng Q., Su J.D., Durden D.L. The protein phosphatase activity of PTEN regulates SRC family kinases and controls glioma migration. Cancer Res. 2008, 68:1862-1871.
19. Gu J., Tamura M., Pankov R., Danen E.H., Takino T., Matsumoto K., Yamada K.M. Shc and FAK differentially regulate cell motility and directionality modulated by PTEN. J. Cell Biol. 1999, 146:389-403.
20. Aikawa R., Nagai T., Kudoh S., Zou Y., Tanaka M., Tamura M., Akazawa H., Takano H., Nagai R., Komuro I. Integrins play a critical role in mechanical stress-induced p38 MAPK activation. Hypertension 2002, 39:233-238.
21. Han J., Lee J.D., Bibbs L., Ulevitch R.J. A MAP kinase targeted by endotoxin and hyperosmolarity in mammalian cells. Science 1994, 265:808-811.
22. Cuadrado A., Nebreda A.R. Mechanisms and functions of p38 MAPK signalling. Biochem. J. 2010, 429:403-417.
23. Coulthard L.R., White D.E., Jones D.L., McDermott M.F., Burchill S.A. p38(MAPK): stress responses from molecular mechanisms to therapeutics. Trends Mol. Med. 2009, 15:369-379.
24. Breton-Romero R., Gonzalez de Orduna C., Romero N., Sanchez-Gomez F.J., de Alvaro C., Porras A., Rodriguez-Pascual F., Laranjinha J., Radi R., Lamas S. Critical role of hydrogen peroxide signaling in the sequential activation of p38 MAPK and eNOS in laminar shear stress. Free Radic. Biol. Med. 2012, 52:1093-1100.
25. Michel T., Li G.K., Busconi L. Phosphorylation and subcellular translocation of endothelial nitric oxide synthase. Proc. Natl. Acad. Sci. U. S. A. 1993, 90:6252-6256.
26. Gonzalez E., Nagiel A., Lin A.J., Golan D.E., Michel T. Small interfering RNA-mediated down-regulation of caveolin-1 differentially modulates signaling pathways in endothelial cells. J. Biol. Chem. 2004, 279:40659-40669.
27. Levine Y.C., Li G.K., Michel T. Agonist-modulated regulation of AMP-activated protein kinase (AMPK) in endothelial cells. Evidence for an AMPK→Rac1→Akt→ endothelial nitric-oxide synthase pathway. J. Biol. Chem. 2007, 282:20351-20364.
28. Kou R., Greif D., Michel T. Dephosphorylation of endothelial nitric-oxide synthase by vascular endothelial growth factor. Implications for the vascular responses to cyclosporin A. J. Biol. Chem. 2002, 277:29669-29673.
29. Aoki K., Kiyokawa E., Nakamura T., Matsuda M. Visualization of growth signal transduction cascades in living cells with genetically encoded probes based on Forster resonance energy transfer. Philos. Trans. R. Soc. Lond. B Biol. Sci. 2008, 363:2143-2151.
30. Zhang W., Liu H.T. MAPK signal pathways in the regulation of cell proliferation in mammalian cells. Cell Res. 2002, 12:9-18.
31. Jiang B.H., Zheng J.Z., Aoki M., Vogt P.K. Phosphatidylinositol 3-kinase signaling mediates angiogenesis and expression of vascular endothelial growth factor in endothelial cells. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:1749-1753.
32. Silva A., Yunes J.A., Cardoso B.A., Martins L.R., Jotta P.Y., Abecasis M., Nowill A.E., Leslie N.R., Cardoso A.A., Barata J.T. PTEN posttranslational inactivation and hyperactivation of the PI3K/Akt pathway sustain primary T cell leukemia viability. J. Clin. Invest. 2008, 118:3762-3774.
33. Morello F., Perino A., Hirsch E. Phosphoinositide 3-kinase signalling in the vascular system. Cardiovasc. Res. 2009, 82:261-271.
34. Fulton D., Gratton J.P., McCabe T.J., Fontana J., Fujio Y., Walsh K., Franke T.F., Papapetropoulos A., Sessa W.C. Regulation of endothelium-derived nitric oxide production by the protein kinase Akt. Nature 1999, 399:597-601.
35. Dimmeler S., Fleming I., Fisslthaler B., Hermann C., Busse R., Zeiher A.M. Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature 1999, 399:601-605.
36. Denise Martin E., De Nicola G.F., Marber M.S. New therapeutic targets in cardiology: p38 alpha mitogen-activated protein kinase for ischemic heart disease. Circulation 2012, 126:357-368.
37. Sicard P., Clark J.E., Jacquet S., Mohammadi S., Arthur J.S., O'Keefe S.J., Marber M.S. The activation of p38 alpha, and not p38 beta, mitogen-activated protein kinase is required for ischemic preconditioning. J. Mol. Cell. Cardiol. 2010, 48:1324-1328.
38. Kumphune S., Bassi R., Jacquet S., Sicard P., Clark J.E., Verma S., Avkiran M., O'Keefe S.J., Marber M.S. A chemical genetic approach reveals that p38alpha MAPK activation by diphosphorylation aggravates myocardial infarction and is prevented by the direct binding of SB203580. J. Biol. Chem. 2010, 285:2968-2975.
39. Insall R.H., Weiner O.D. PIP3, PIP2, and cell movement - similar messages, different meanings?. Dev. Cell 2001, 1:743-747.
40. Niggli V. A membrane-permeant ester of phosphatidylinositol 3,4,5-trisphosphate (PIP(3)) is an activator of human neutrophil migration. FEBS Lett. 2000, 473:217-221.
41. Takenawa T., Miki H. WASP and WAVE family proteins: key molecules for rapid rearrangement of cortical actin filaments and cell movement. J. Cell Sci. 2001, 114:1801-1809.
42. Bishop A.L., Hall A. Rho GTPases and their effector proteins. Biochem. J. 2000, 348(Pt 2):241-255.
43. Gordon J.L. Extracellular ATP: effects, sources and fate. Biochem. J. 1986, 233:309-319.
44. Mills D.C., Robb I.A., Roberts G.C. The release of nucleotides, 5-hydroxytryptamine and enzymes from human blood platelets during aggregation. J. Physiol. 1968, 195:715-729.
45. Stiles B., Groszer M., Wang S., Jiao J., Wu H. PTENless means more. Dev. Biol. 2004, 273:175-184.
46. Keyes K.T., Xu J., Long B., Zhang C., Hu Z., Ye Y. Pharmacological inhibition of PTEN limits myocardial infarct size and improves left ventricular function postinfarction. Am. J. Physiol. Heart Circ. Physiol. 2010, 298:H1198-H1208.
47. Shen Y.H., Zhang L., Utama B., Wang J., Gan Y., Wang X., Chen L., Vercellotti G.M., Coselli J.S., Mehta J.L., Wang X.L. Human cytomegalovirus inhibits Akt-mediated eNOS activation through upregulating PTEN (phosphatase and tensin homolog deleted on chromosome 10). Cardiovasc. Res. 2006, 69:502-511.
48. Song M.S., Salmena L., Pandolfi P.P. The functions and regulation of the PTEN tumour suppressor. Nat. Rev. Mol. Cell Biol. 2012, 13:283-296.
49. Dudzinski D.M., Michel T. Life history of eNOS: partners and pathways. Cardiovasc. Res. 2007, 75:247-260.
50. Guns P.J., Korda A., Crauwels H.M., Van Assche T., Robaye B., Boeynaems J.M., Bult H. Pharmacological characterization of nucleotide P2Y receptors on endothelial cells of the mouse aorta. Br. J. Pharmacol. 2005, 146:288-295.
51. Myers M.P., Pass I., Batty I.H., Van der Kaay J., Stolarov J.P., Hemmings B.A., Wigler M.H., Downes C.P., Tonks N.K. The lipid phosphatase activity of PTEN is critical for its tumor suppressor function. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:13513-13518.
52. Salmena L., Carracedo A., Pandolfi P.P. Tenets of PTEN tumor suppression. Cell 2008, 133:403-414.
53. Franca-Koh J., Kamimura Y., Devreotes P.N. Leading-edge research: PtdIns(3,4,5)P3 and directed migration. Nat. Cell Biol. 2007, 9:15-17.
54. Nobes C.D., Hall A. Rho, rac, and cdc42 GTPases regulate the assembly of multimolecular focal complexes associated with actin stress fibers, lamellipodia, and filopodia. Cell 1995, 81:53-62.
55. Hall A. Rho GTPases and the actin cytoskeleton. Science 1998, 279:509-514.